SC 53228

Drug Profile

SC 53228

Latest Information Update: 28 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacia Corporation
  • Class Anti-inflammatories; Benzopyrans
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Dermatitis; Psoriasis; Ulcerative colitis

Most Recent Events

  • 16 Apr 2003 Pharmacia has been acquired by Pfizer
  • 03 Nov 1998 No-Development-Reported for Ulcerative colitis in USA (PO)
  • 22 Sep 1998 No-Development-Reported for Dermatitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top